Peer-reviewed veterinary case report
Heart meds before heart failure may help small dogs with valve
By Park, Sin-Wook et al.·Published in The veterinary quarterly·2025·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Impact of administering cardiac medication to small-breed dogs with preclinical myxomatous mitral valve disease on survival after congestive heart failure onset.
- Species:
- dog
Plain-English summary
A study looked at small-breed dogs with a common heart condition called myxomatous mitral valve disease (MMVD) that can lead to congestive heart failure (CHF). It found that dogs who received heart medication like pimobendan before developing CHF actually had shorter survival times after the onset of CHF compared to those who did not receive treatment beforehand. Specifically, untreated dogs survived a median of 481 days after CHF onset, while those treated with medication survived only 212 days. This suggests that starting heart medications early may not help these dogs live longer once CHF develops.
People also search for: small dog heart disease treatment · congestive heart failure in dogs · pimobendan for dogs · myxomatous mitral valve disease prognosis
Abstract
Myxomatous mitral valve disease (MMVD) is the most common cardiovascular disease in small-breed dogs, and some affected dogs develop congestive heart failure (CHF). Although pimobendan is recommended to delay the onset of CHF, its effect on survival following CHF onset development remains unclear. This retrospective study evaluated the survival prognosis of 143 small-breed dogs diagnosed with first-time CHF due to MMVD, comparing pretreated ( = 54) and untreated ( = 89) groups. Pretreated dogs received cardiac medications including pimobendan for at least five weeks before CHF onset. Pretreated dogs had a significantly larger normalized left ventricular internal diameter (LVIDDN; = 0.002) and higher left atrium-to-aortic root ratio (LA/Ao; = 0.044) at CHF onset than untreated dogs. The median survival time after CHF onset was significantly longer in untreated dogs (481 days, 95% confidence interval (CI) 393-569 days) than in pretreated dogs (212 days, 95% CI 73-351 days; = 0.028). Univariable Cox proportional hazards analysis identified pretreatment ( = 0.031), chordae tendineae rupture ( = 0.011), and the LA/Ao ( < 0.001) as significant predictors of survival. Our findings suggest that the administration of cardiac medications, including pimobendan, prior to the onset of CHF was not independently associated with improved survival following CHF.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40975815/